Boundless Bio Inc. （BOLD.US） 2Q24 Update： Proof of Concept data for both ‘355 and ‘825 now expected in 2H25. With measures， cash

Investment Rating - The report does not provide a specific investment rating for Boundless Bio Inc. (BOLD) [8][20]. Core Insights - The timelines for clinical data reporting for BBI-355 and BBI-825 have been adjusted to the second half of 2025, delayed from the previous expectation of the second half of 2024 [5][6]. - Management is implementing measures to enhance enrollment in the Phase 1/2 POTENTIATE clinical trial, including expanding trial sites and collaborating with multiple NGS providers [4][5]. - The company has a cash position of $179.3 million, which is expected to provide a runway into the fourth quarter of 2026, extending guidance from the previous second half of 2026 [6]. Summary by Sections BBI-355 (CHK1 Inhibitor) - The initial clinical data for BBI-355 is now expected in the second half of 2025, with management aiming to present data involving a sufficient number of patients for informed assessments [5][6]. - The cohort involving combination with CDK4/6 is expected to initiate by the end of 2024 or early 2025 [5]. BBI-825 (RNR Inhibitor) - The STARMAP trial for BBI-825 is ongoing, with the first patient dosed in April 2024, showing encouraging bioavailability and good tolerability [5][6]. - Data from the Phase 1/2 trial is anticipated to be shared in the second half of 2025 [5]. Financial Guidance and Model Updates - The report indicates that the steps taken by management to enhance trial enrollment are prudent, and the cash position allows for extended operational runway [6]. - Current estimates for potential approval and commercialization of BBI-355 remain intact at 2028, with ongoing monitoring of enrollment efforts [6].